These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

133 related articles for article (PubMed ID: 8527591)

  • 1. Efficacy of intermittent liposomal amphotericin B in the treatment of visceral leishmaniasis in patients infected with human immunodeficiency virus.
    Laguna F; Torre-Cisneros J; Moreno V; Villanueva JL; Valencia E
    Clin Infect Dis; 1995 Sep; 21(3):711-2. PubMed ID: 8527591
    [No Abstract]   [Full Text] [Related]  

  • 2. Efficacy of liposomal amphotericin B in the treatment of visceral leishmaniasis in patients coinfected with the human immunodeficiency virus.
    Torre-Cisneros J; Villanueva JL
    Clin Infect Dis; 1995 Jan; 20(1):191. PubMed ID: 7727652
    [No Abstract]   [Full Text] [Related]  

  • 3. Efficacy of liposomal amphotericin B in the treatment and secondary prophylaxis of visceral leishmaniasis in HIV infected patients: report of two cases.
    Lopez Dupla M; Gil Aguado A; Lavilla Uriol P; Pintado Garcia V; Valencia Ortega E; Martinez Martinez P; Garcia-Puig J
    J Antimicrob Chemother; 1993 Oct; 32(4):657-9. PubMed ID: 8288512
    [No Abstract]   [Full Text] [Related]  

  • 4. Successful treatment of antimony-resistant visceral leishmaniasis with liposomal amphotericin B in patients infected with human immunodeficiency virus.
    Torre-Cisneros J; Villanueva JL; Kindelan JM; Jurado R; Sanchez-Guijo P
    Clin Infect Dis; 1993 Oct; 17(4):625-7. PubMed ID: 8268341
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Cutaneous manifestations of visceral leishmaniasis resistant to liposomal amphotericin B in an HIV-positive patient.
    Alsina-Gibert M; López-Lerma I; Martinez-Chamorro E; Herrero-Mateu C
    Arch Dermatol; 2006 Jun; 142(6):787-9. PubMed ID: 16785393
    [No Abstract]   [Full Text] [Related]  

  • 6. Visceral leishmaniasis in HIV infected patients: treatment with high dose liposomal amphotericin B (AmBisome).
    Russo R; Nigro LC; Minniti S; Montineri A; Gradoni L; Caldeira L; Davidson RN
    J Infect; 1996 Mar; 32(2):133-7. PubMed ID: 8708370
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Liposomal amphotericin B for the treatment of visceral leishmaniasis.
    Bern C; Adler-Moore J; Berenguer J; Boelaert M; den Boer M; Davidson RN; Figueras C; Gradoni L; Kafetzis DA; Ritmeijer K; Rosenthal E; Royce C; Russo R; Sundar S; Alvar J
    Clin Infect Dis; 2006 Oct; 43(7):917-24. PubMed ID: 16941377
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Liposomal amphotericin B (AmBisome) in Mediterranean visceral leishmaniasis: a multi-centre trial.
    Davidson RN; Di Martino L; Gradoni L; Giacchino R; Russo R; Gaeta GB; Pempinello R; Scott S; Raimondi F; Cascio A
    Q J Med; 1994 Feb; 87(2):75-81. PubMed ID: 8153291
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Diffuse cutaneous dissemination of visceral leishmaniasis during human immunodeficiency virus (HIV) infection, despite negligible immunodeficiency: repeated failure of liposomal amphotericin B administration, followed by successful long-term pentamidine and paromomycin administration.
    Manfredi R; Marinacci G; Calza L; Passarini B
    Int J Antimicrob Agents; 2008 Jun; 31(6):590-2. PubMed ID: 18456464
    [No Abstract]   [Full Text] [Related]  

  • 10. Post-Kala-Azar dermal leishmaniasis in an HIV-1-infected woman: recovery after amphotericin B following failure of oral miltefosine.
    Guffanti M; Gaiera G; Bossolasco S; Ceserani N; Ratti D; Cinque P; Salmaso F; Gianotti N; Lazzarin A
    Am J Trop Med Hyg; 2008 Nov; 79(5):715-8. PubMed ID: 18981510
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Treatment of visceral leishmaniasis with a 10 day course of L-ampB-LRC (Bombay), a liposomal amphotericin B.
    Bodhe PV; Pathare AV; Kshirsagar NA; Pandya SK
    J Assoc Physicians India; 1996 Mar; 44(3):222. PubMed ID: 9251329
    [No Abstract]   [Full Text] [Related]  

  • 12. Comment on: Efficacy of liposomal amphotericin B for secondary prophylaxis of visceral leishmaniasis in HIV-infected patients.
    Collazos J
    J Antimicrob Chemother; 2008 Feb; 61(2):466-7; author reply 467. PubMed ID: 18077312
    [No Abstract]   [Full Text] [Related]  

  • 13. Liposomal amphotericin B in drug-resistant visceral leishmaniasis.
    Davidson RN; Croft SL; Scott A; Maini M; Moody AH; Bryceson AD
    Lancet; 1991 May; 337(8749):1061-2. PubMed ID: 1673494
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Visceral leishmaniasis associated with human immunodeficiency virus infection (reply)].
    Berenguer J; Cosín J; Miralles P; López JC; Padilla B
    Enferm Infecc Microbiol Clin; 2002 Mar; 20(3):133. PubMed ID: 11904089
    [No Abstract]   [Full Text] [Related]  

  • 15. Successful treatment of antimony-resistant visceral leishmaniasis with liposomal amphotericin B (L-AmpB-LRC) in a child.
    Karande SC; Boby KF; Lahiri KR; Jain MK; Kshirsagar NA; Gokhale PC; Pandya SK
    Trop Doct; 1995 Apr; 25(2):80-1. PubMed ID: 7778200
    [No Abstract]   [Full Text] [Related]  

  • 16. [Treatment of visceral Leismaniasis in HIV patients with a new regimen of liposomal amphotericin].
    Canora Lebrato J; Troncoso García E; Escobar T; Hernández Quero J
    Med Clin (Barc); 2001 Mar; 116(10):395. PubMed ID: 11333677
    [No Abstract]   [Full Text] [Related]  

  • 17. Liposomal amphotericin B and rHuGM-CSF for treatment of visceral leishmaniasis in AIDS.
    Mastroianni A
    Infez Med; 2004 Sep; 12(3):197-204. PubMed ID: 15711134
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Efficacy and tolerability of liposomal amphotericin B in Italian infants with visceral leishmaniasis.
    di Martino L; Raimondi F; Scotti S; Davidson RN; Gradoni L; Giacchino R
    Trans R Soc Trop Med Hyg; 1993; 87(4):477. PubMed ID: 8249088
    [No Abstract]   [Full Text] [Related]  

  • 19. Efficacy and tolerance of amphotericin B in a lipid emulsion in the treatment of visceral leishmaniasis in AIDS patients.
    Petit N; Parola P; Dhiver C; Gastaut JA
    J Antimicrob Chemother; 1996 Jul; 38(1):154-7. PubMed ID: 8858471
    [No Abstract]   [Full Text] [Related]  

  • 20. Liposomal amphotericin B for leishmaniasis treatment of AIDS patients unresponsive to antimonium compounds.
    Lazanas MC; Tsekes GA; Papandreou S; Harhalakis N; Scandali A; Nikiforakis E; Saroglou G
    AIDS; 1993 Jul; 7(7):1018-9. PubMed ID: 8357549
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 7.